Header Logo

Connection

HOWARD WEINER to Disease Progression

Back to Details
This is a "connection" page, showing publications HOWARD WEINER has written about Disease Progression.
HOWARD WEINER
Connection Strength
0.729
Disease Progression
  1. Stool Glial Fibrillary Acidic Protein Is Elevated in Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Nov; 12(6):e200466.
    View in: PubMed
    Score: 0.146
  2. A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. J Neurosurg Pediatr. 2014 Jan; 13(1):21-8.
    View in: PubMed
    Score: 0.064
  3. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.055
  4. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):75-9.
    View in: PubMed
    Score: 0.049
  5. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.045
  6. Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry. 2025 Oct 15; 96(11):1046-1052.
    View in: PubMed
    Score: 0.037
  7. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
    View in: PubMed
    Score: 0.030
  8. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. J Neuroimaging. 2020 03; 30(2):212-218.
    View in: PubMed
    Score: 0.025
  9. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
    View in: PubMed
    Score: 0.024
  10. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019 05; 22(5):729-740.
    View in: PubMed
    Score: 0.023
  11. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.022
  12. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 10; 24(11):1485-1498.
    View in: PubMed
    Score: 0.021
  13. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12; 387(10023):1075-1084.
    View in: PubMed
    Score: 0.019
  14. Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation. Circ Res. 2015 Oct 09; 117(9):779-92.
    View in: PubMed
    Score: 0.018
  15. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology. 2014 Dec 09; 83(24):2219-26.
    View in: PubMed
    Score: 0.017
  16. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.017
  17. Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE. Exp Neurol. 2014 May; 255:63-70.
    View in: PubMed
    Score: 0.016
  18. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.015
  19. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
    View in: PubMed
    Score: 0.013
  20. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.012
  21. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb; 66(2):234-7.
    View in: PubMed
    Score: 0.012
  22. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.012
  23. MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol. 2007 Nov-Dec; 28(10):1956-63.
    View in: PubMed
    Score: 0.011
  24. Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? Neurotherapeutics. 2007 Jul; 4(3):485-98.
    View in: PubMed
    Score: 0.010
  25. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004 Dec 15; 22(24):4881-7.
    View in: PubMed
    Score: 0.009
  26. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003 Feb 25; 60(4):640-6.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.